WO2002047722A1 - Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions - Google Patents

Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions Download PDF

Info

Publication number
WO2002047722A1
WO2002047722A1 PCT/JP2001/010956 JP0110956W WO0247722A1 WO 2002047722 A1 WO2002047722 A1 WO 2002047722A1 JP 0110956 W JP0110956 W JP 0110956W WO 0247722 A1 WO0247722 A1 WO 0247722A1
Authority
WO
WIPO (PCT)
Prior art keywords
nonpeptidyl
antagonist
gonadotropin
releasing hormone
medicinal compositions
Prior art date
Application number
PCT/JP2001/010956
Other languages
English (en)
Japanese (ja)
Inventor
Hiroshi Suzuki
Yoshio Hata
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU2002221139A priority Critical patent/AU2002221139A1/en
Publication of WO2002047722A1 publication Critical patent/WO2002047722A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

L'invention concerne des compositions médicinales comprenant: i) un agoniste ou un antagoniste de la gonadolibérine non peptidyl; ii) un acide organique ou son sel; et iii) un polymère biodégradable ou son sel. Ces compositions peuvent être produites efficacement, ne s'exposent à aucun problème de contrôle de qualité, et peuvent présenter une vitesse de libération stable sur une longue durée, même lorsque l'agoniste ou l'antagoniste de la gonadolibérine non peptidyl est présent en grande quantité, indépendamment de sa solubilité, de son point de fusion ou de sa cristallinité. , méthode de production et utilisation desdites compositions
PCT/JP2001/010956 2000-12-15 2001-12-14 Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions WO2002047722A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002221139A AU2002221139A1 (en) 2000-12-15 2001-12-14 Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-382431 2000-12-15
JP2000382431 2000-12-15

Publications (1)

Publication Number Publication Date
WO2002047722A1 true WO2002047722A1 (fr) 2002-06-20

Family

ID=18850254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010956 WO2002047722A1 (fr) 2000-12-15 2001-12-14 Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions

Country Status (2)

Country Link
AU (1) AU2002221139A1 (fr)
WO (1) WO2002047722A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002092A3 (fr) * 2001-06-29 2003-04-10 Takeda Chemical Industries Ltd Composition a liberation controlee et procede de production de cette composition
WO2004067535A1 (fr) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited Composes de thienopyrimidine et utilisation
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626170A2 (fr) * 1993-05-10 1994-11-30 Sandoz Ltd. Stabilisation de composés pharmacoligiquement actifs dans des compositions à libération contrôlée
WO1995015767A1 (fr) * 1993-12-09 1995-06-15 Asta Medica Aktiengesellschaft Suspensions pour injection a action prolongee et procede de preparation
WO1995028405A1 (fr) * 1994-04-19 1995-10-26 Takeda Chemical Industries, Ltd. Derives du thiopene bicyclique et utilisation commme antagonistes de la gonadoliberine
WO1996024597A1 (fr) * 1995-02-08 1996-08-15 Takeda Chemical Industries, Ltd. Derives a base de thienopyrimidine, leur production et leurs utilisations
WO1998032423A1 (fr) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Microspheres a liberation prolongee, leur production et utilisation
WO1999036099A1 (fr) * 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Compositions a liberation controlee, leur procede de fabrication et leur utilisation
WO2000056739A1 (fr) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Composes de thienopyrimidine, leur production et leur utilisation
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626170A2 (fr) * 1993-05-10 1994-11-30 Sandoz Ltd. Stabilisation de composés pharmacoligiquement actifs dans des compositions à libération contrôlée
WO1995015767A1 (fr) * 1993-12-09 1995-06-15 Asta Medica Aktiengesellschaft Suspensions pour injection a action prolongee et procede de preparation
WO1995028405A1 (fr) * 1994-04-19 1995-10-26 Takeda Chemical Industries, Ltd. Derives du thiopene bicyclique et utilisation commme antagonistes de la gonadoliberine
WO1996024597A1 (fr) * 1995-02-08 1996-08-15 Takeda Chemical Industries, Ltd. Derives a base de thienopyrimidine, leur production et leurs utilisations
WO1998032423A1 (fr) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Microspheres a liberation prolongee, leur production et utilisation
WO1999036099A1 (fr) * 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Compositions a liberation controlee, leur procede de fabrication et leur utilisation
WO2000056739A1 (fr) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Composes de thienopyrimidine, leur production et leur utilisation
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067030B2 (en) 2001-06-29 2011-11-29 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
US8815801B2 (en) 2001-06-29 2014-08-26 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
EP1491236A1 (fr) * 2001-06-29 2004-12-29 Takeda Chemical Industries, Ltd. Composition pharmaceutique orale a libération controlée contenant des polymeres d'acide lactique, de l'acide hydroxynaphtoique, et son procédé de préparation
US8246987B2 (en) 2001-06-29 2012-08-21 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
WO2003002092A3 (fr) * 2001-06-29 2003-04-10 Takeda Chemical Industries Ltd Composition a liberation controlee et procede de production de cette composition
US7429559B2 (en) 2001-06-29 2008-09-30 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
EP1949936A3 (fr) * 2001-06-29 2008-10-08 Takeda Pharmaceutical Company Limited Composition à libération contrôlée et son procédé de production
CN100360538C (zh) * 2003-01-29 2008-01-09 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
US8058280B2 (en) 2003-01-29 2011-11-15 Takeda Pharmaceutical Company Limited Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
US8735401B2 (en) 2003-01-29 2014-05-27 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
WO2004067535A1 (fr) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited Composes de thienopyrimidine et utilisation
US9346822B2 (en) 2003-01-29 2016-05-24 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US9617303B2 (en) 2006-12-18 2017-04-11 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US9713595B2 (en) 2006-12-18 2017-07-25 Takeda Pharmaceuticals Company Limited Sustained-release composition and method for producing the same

Also Published As

Publication number Publication date
AU2002221139A1 (en) 2002-06-24

Similar Documents

Publication Publication Date Title
AU7939298A (en) An itraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
AU8142594A (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
TWI235068B (en) Sustained-release pharmaceutical composition
AU3787699A (en) Aqueous process for manufacturing paroxetine solid dispersions
CA2396159A1 (fr) Nouvelles formes posologiques de benzimidazole substitue
CA2361716A1 (fr) Procede de preparation de salicylamides alkyles
CA2386516A1 (fr) Composition liquide multicouche
EP1203766A3 (fr) Dérivés d'acides carboxyliques inhibant la liaison des intégrines à leurs récepteurs
CA2317106A1 (fr) Procede et composition d'une preparation orale d'itraconazole
AU2001278696A1 (en) Aqueous pharmaceutical compositions
HK1092485A1 (en) Method of manufacture of polyacrolein
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
WO2002014403A3 (fr) Copolymeres de poly(d,l-lactide-co-glycolide) a groupe terminal acide et a teneur importante en glycolide
WO2000041528A3 (fr) Compositions a liberation controlee amelioree et son procede
CA2290893A1 (fr) Omeprazole de magnesium
WO2006010155A3 (fr) Antagonistes de l'hormone de liberation de la gonadotropine
WO2002047722A1 (fr) Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
WO2002042315A3 (fr) Solvates macrolides
CA2393757A1 (fr) Antagonistes du recepteur ccr5 de la cycloamine
ID26346A (id) PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT
AU3550100A (en) Biodegradable, injectable oligomer-polymer composition
WO2001003666A3 (fr) Compositions pour occlusion vasculaire a base de liquide
AU9259501A (en) Interphenylene 7-oxabicyclic(2.2.1)heptane oxazoles as prostaglandin F<sub>2alpha</sub> antagonists
WO2002043766A1 (fr) Compositions medicinales et leur procede de preparation
RU99116432A (ru) Способ иммобилизации физиологически активных соединений

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP